EPISODE · Jan 2, 2026 · 20 MIN
Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained - Dr. Bill Gradishar & Dr. Tiffany Traina
from Community Health Media · host Community Health Media
In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer.They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, toxicity profiles, and what truly differentiates datopotamab deruxtecan from sacituzumab govitecan in real-world practice.From refractory disease and disease-free interval definitions to logistics, crossover design, brain metastases, and patient-centered decision-making, this discussion offers practical insight into how clinicians should think about therapy selection, sequencing, and shared decision-making in mTNBC today.🎧 A must-watch episode for oncologists navigating the rapidly evolving TNBC treatment landscape.#TripleNegativeBreastCancer #TNBC #Oncology #BreastCancer #AntibodyDrugConjugates #ADCs #Datopotamab #Sacituzumab #CancerResearch #MedicalOncology #ClinicalTrials #PrecisionOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media
Embed this episode
Ready to play
Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained - Dr. Bill Gradishar & Dr. Tiffany Traina
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.